{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:10:58Z","timestamp":1792829458479,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00724-1","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:46:30Z","timestamp":1771490790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Willingness to pay for a quality-adjusted life year in Iran: a systematic review"],"prefix":"10.1186","volume":"24","author":[{"given":"Reza","family":"Hashempour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"AbolhasanBeigi Gallehzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Akhavan Rezayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Raei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-6554","authenticated-orcid":false,"given":"Sara","family":"Emamgholipour Sefiddashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"724_CR1","first-page":"1","volume":"17","author":"N Moradi","year":"2019","unstructured":"Moradi N, Rashidian A, Nosratnejad S, Olyaeemanesh A, Zanganeh M, Zarei L. Willingness to pay for one quality-adjusted life year in Iran. Cost Eff Resource Allocation. 2019;17:1\u201310.","journal-title":"Cost Eff Resource Allocation"},{"key":"724_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, Hill SR. Cost\u2013effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94:925.","journal-title":"Bull World Health Organ"},{"key":"724_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1017\/S0266462300004803","volume":"7","author":"CE Phelps","year":"1991","unstructured":"Phelps CE, Mushlin AI. On the (near) equivalence of cost-effectiveness and cost-benefit analyses. Int J Technol Assess Health Care. 1991;7:12\u201321.","journal-title":"Int J Technol Assess Health Care"},{"key":"724_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10198-021-01364-3","volume":"23","author":"CR Kouakou","year":"2022","unstructured":"Kouakou CR, Poder TG. Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression. Eur J Health Econ. 2022;23:277\u201399.","journal-title":"Eur J Health Econ"},{"key":"724_CR5","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","volume":"12","author":"MC Weinstein","year":"2009","unstructured":"Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12:S5\u20139.","journal-title":"Value Health"},{"key":"724_CR6","doi-asserted-by":"publisher","first-page":"E601","DOI":"10.1001\/amajethics.2021.601","volume":"23","author":"P Menzel","year":"2021","unstructured":"Menzel P. How should Willingness-to-Pay values of Quality-Adjusted Life-Years be updated and according to whom? AMA J Ethics. 2021;23:E601\u2013606.","journal-title":"AMA J Ethics"},{"key":"724_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1590\/S0034-89102009005000007","volume":"43","author":"JF Mould Quevedo","year":"2009","unstructured":"Mould Quevedo JF, Contreras Hern\u00e1ndez I, Gardu\u00f1o Espinosa J, Salinas Escudero G. The willingness-to-pay concept in question. Rev Saude Publica. 2009;43:352\u20138.","journal-title":"Rev Saude Publica"},{"key":"724_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12962-024-00593-6","volume":"22","author":"A Olyaeemanesh","year":"2024","unstructured":"Olyaeemanesh A, Habibi F, Mobinizadeh M, Takian A, Khosravi B, Jafarzadeh J, Bakhtiari A, Mohamadi E. Identifying and prioritizing inefficiency causes in iran\u2019s health system. Cost Eff Resource Allocation. 2024;22:81.","journal-title":"Cost Eff Resource Allocation"},{"key":"724_CR9","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1186\/s12913-021-07344-w","volume":"21","author":"S-F Jahanbin","year":"2021","unstructured":"Jahanbin S-F, Yusefzadeh H, Nabilou B, Alinia C. Value of willingness to pay for a QALY gained in Iran; a modified chained-approach. BMC Health Serv Res. 2021;21:1339.","journal-title":"BMC Health Serv Res"},{"key":"724_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","volume":"25","author":"J Kazibwe","year":"2022","unstructured":"Kazibwe J, Gheorghe A, Wilson D, Ruiz F, Chalkidou K, Chi Y-L. The use of cost-effectiveness thresholds for evaluating health interventions in low-and middle-income countries from 2015 to 2020: a review. Value Health. 2022;25:385\u20139.","journal-title":"Value Health"},{"key":"724_CR11","doi-asserted-by":"crossref","unstructured":"Rehman F, Shahid MW, Riaz M, Umair MM, Azhar F, Amer M, Ahmed A. Willingness to pay for a quality-adjusted life year (QALY) in pakistan: implications for health policy. Expert Rev PharmacoEcon Outcomes Res. 2025:1\u20139.","DOI":"10.1080\/14737167.2025.2504945"},{"key":"724_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40273-013-0110-1","volume":"32","author":"A Bobinac","year":"2014","unstructured":"Bobinac A, van Exel J, Rutten FF, Brouwer WB. The value of a QALY: individual willingness to pay for health gains under risk. PharmacoEconomics. 2014;32:75\u201386.","journal-title":"PharmacoEconomics"},{"key":"724_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.socscimed.2018.06.009","volume":"211","author":"L Huang","year":"2018","unstructured":"Huang L, Frijters P, Dalziel K, Clarke P. Life satisfaction, QALYs, and the monetary value of health. Soc Sci Med. 2018;211:131\u20136.","journal-title":"Soc Sci Med"},{"key":"724_CR14","doi-asserted-by":"crossref","unstructured":"Xu L, Chen M, Angell B, Jiang Y, Howard K, Jan S, Si L. Establishing cost-effectiveness threshold in china: a community survey of willingness to pay for a healthy life year. BMJ Global Health. 2024;9.","DOI":"10.1136\/bmjgh-2023-013070"},{"key":"724_CR15","first-page":"321","volume":"30","author":"F Mohtasham","year":"2016","unstructured":"Mohtasham F, Yazdizadeh B, Zali Z, Majdzadeh R, Nedjat S. Health technology assessment in iran: barriers and solutions. Med J Islamic Repub Iran. 2016;30:321.","journal-title":"Med J Islamic Repub Iran"},{"key":"724_CR16","doi-asserted-by":"crossref","unstructured":"Appleby J, Devlin N, Parkin D. NICE\u2019s cost effectiveness threshold. BMJ. 2007;335:358\u20139.","DOI":"10.1136\/bmj.39308.560069.BE"},{"key":"724_CR17","doi-asserted-by":"crossref","unstructured":"Barnsley P, Towse A, Sussex J. Critique of CHE research paper 81: methods for the Estimation of the NICE cost effectiveness threshold. Sarah Sussex Jonathan Mark Critique CHE Res Paper. 2013;81.","DOI":"10.2139\/ssrn.2637927"},{"key":"724_CR18","doi-asserted-by":"crossref","unstructured":"Calxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S. Methods for the Estimation of the NICE cost effectiveness threshold. Health Technol Assess. 2015;19.","DOI":"10.3310\/hta19140"},{"key":"724_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","volume":"19","author":"K Claxton","year":"2015","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the Estimation of the National Institute for health and care excellence cost-effectiveness threshold. Health Technol Assess (Winchester Eng). 2015;19:1.","journal-title":"Health Technol Assess (Winchester Eng)"},{"key":"724_CR20","doi-asserted-by":"publisher","first-page":"e0266934","DOI":"10.1371\/journal.pone.0266934","volume":"17","author":"H Iino","year":"2022","unstructured":"Iino H, Hashiguchi M, Hori S. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review. PLoS ONE. 2022;17:e0266934.","journal-title":"PLoS ONE"},{"key":"724_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/14737167.2021.1878881","volume":"22","author":"Z Ye","year":"2022","unstructured":"Ye Z, Ma J, Liu F, Wang C, Zhou Z, Sun L. A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population. Expert Rev PharmacoEcon Outcomes Res. 2022;22:53\u201361.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"724_CR22","doi-asserted-by":"crossref","unstructured":"Safari H, Poder TG, Afshari S, Nahvijou A, Arab-Zozani M, Moradi N, Ameri H. Determination of a cost-effectiveness threshold for cancer interventions in Iran. Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.1039589"},{"key":"724_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s41669-018-0111-2","volume":"3","author":"N Moradi","year":"2019","unstructured":"Moradi N, Rashidian A, Nosratnejad S, Olyaeemanesh A, Zanganeh M, Zarei L. The worth of a quality-adjusted life-year in patients with diabetes: an investigation study using a willingness-to-pay method. PharmacoEconomics-open. 2019;3:311\u20139.","journal-title":"PharmacoEconomics-open"},{"key":"724_CR24","doi-asserted-by":"crossref","unstructured":"Jahanbin SF, Yusefzadeh H, Nabilou B, Alinia C. Value of willingness to pay for a QALY gained in Iran; a modified chained-approach. BMC Health Serv Res. 2021;21.","DOI":"10.1186\/s12913-021-07344-w"},{"key":"724_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40258-018-0424-4","volume":"16","author":"KB Lankarani","year":"2018","unstructured":"Lankarani KB, Ghahramani S, Moradi N, Shahraki HR, Lotfi F, Honarvar B. Willingness-to-Pay for one Quality-Adjusted Life-Year: A Population-Based study from Iran. Appl Health Econ Health Policy. 2018;16:837\u201346.","journal-title":"Appl Health Econ Health Policy"},{"key":"724_CR26","doi-asserted-by":"crossref","unstructured":"Moradi N, Rashidian A, Nosratnejad S, Olyaeemanesh A, Zanganeh M, Zarei L. Willingness to pay for one quality-adjusted life year in Iran. Cost Eff Resource Allocation. 2019;17.","DOI":"10.1186\/s12962-019-0172-9"},{"key":"724_CR27","doi-asserted-by":"crossref","unstructured":"Moradi N, Woldemichael A, Malekian P, Rotvandi DM, Rezaei S. An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in Western Iran. Cost Eff Resource Allocation. 2020;18.","DOI":"10.1186\/s12962-020-00241-9"},{"key":"724_CR28","first-page":"820","volume":"16","author":"N Moradi","year":"2017","unstructured":"Moradi N, Rashidian A, Rasekh HR, Olyaeemanesh A, Foroughi M, Mohammadi T. Monetary value of quality-adjusted life years (QALY) among patients with cardiovascular disease: A willingness to pay study (WTP). Iran J Pharm Res. 2017;16:820\u201330.","journal-title":"Iran J Pharm Res"},{"key":"724_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.34172\/doh.2025.06","volume":"16","author":"S Nourifard","year":"2025","unstructured":"Nourifard S, Ghaffari S, Yousefi M. An Estimation of Cost-Effectiveness threshold: calculating the monetary value of a Quality-Adjusted life year. Depiction Health. 2025;16:52\u201367.","journal-title":"Depiction Health"},{"key":"724_CR30","first-page":"823","volume":"16","author":"N Moradi","year":"2017","unstructured":"Moradi N, Rashidian A, Rasekh HR, Olyaeemanesh A, Foroughi M, Mohammadi T. Monetary value of quality-adjusted life years (QALY) among patients with cardiovascular disease: a willingness to pay study (WTP). Iran J Pharm Research: IJPR. 2017;16:823.","journal-title":"Iran J Pharm Research: IJPR"},{"key":"724_CR31","doi-asserted-by":"publisher","first-page":"A617","DOI":"10.1016\/j.jval.2015.09.2151","volume":"18","author":"N Moradi","year":"2015","unstructured":"Moradi N, Rashidian A. Willingness to pay for quality-adjusted life years in patients with diabete. Value Health. 2015;18:A617.","journal-title":"Value Health"},{"key":"724_CR32","doi-asserted-by":"publisher","first-page":"1039589","DOI":"10.3389\/fonc.2022.1039589","volume":"12","author":"H Safari","year":"2022","unstructured":"Safari H, Poder TG, Afshari S, Nahvijou A, Arab-Zozani M, Moradi N, Ameri H. Determination of a cost-effectiveness threshold for cancer interventions in Iran. Front Oncol. 2022;12:1039589.","journal-title":"Front Oncol"},{"key":"724_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12962-021-00260-0","volume":"19","author":"R Daroudi","year":"2021","unstructured":"Daroudi R, Akbari Sari A, Nahvijou A, Faramarzi A. Cost per DALY averted in low, middle-and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds. Cost Eff Resource Allocation. 2021;19:7.","journal-title":"Cost Eff Resource Allocation"},{"key":"724_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.12688\/f1000research.131230.2","volume":"12","author":"T Drake","year":"2024","unstructured":"Drake T, Chi Y-L, Morton A, Pitt C. Why cost-effectiveness thresholds for global health donors should differ from thresholds for ministries of health (and why it matters). F1000Research. 2024;12:214.","journal-title":"F1000Research"},{"key":"724_CR35","unstructured":"Endalew B. Non-market measurement techniques of willingness to pay, the case of environmental resources: a review. 2019."},{"key":"724_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12911-020-01142-w","volume":"20","author":"C Whichello","year":"2020","unstructured":"Whichello C, Levitan B, Juhaeri J, Patadia V, DiSantostefano R, Pinto CA, de Bekker-Grob EW. Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison. BMC Med Inf Decis Mak. 2020;20:114.","journal-title":"BMC Med Inf Decis Mak"},{"key":"724_CR37","unstructured":"Obradovic M. Searching for the social value of a QALY in the Netherlands: the willingness to pay for a QALY. 2012."},{"key":"724_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1055\/s-2006-940066","volume":"34","author":"OH G\u00fcnther","year":"2007","unstructured":"G\u00fcnther OH, Friemel S, Bernert S, Matschinger H, Angermeyer MC, K\u00f6nig H-H. The burden of depressive disorders in Germany-results from the European study of the epidemiology of mental disorders (ESEMeD). Psychiatr Prax. 2007;34:292\u2013301.","journal-title":"Psychiatr Prax"},{"key":"724_CR39","doi-asserted-by":"publisher","first-page":"e000964","DOI":"10.1136\/bmjgh-2018-000964","volume":"3","author":"J Ochalek","year":"2018","unstructured":"Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health. 2018;3:e000964.","journal-title":"BMJ Global Health"},{"key":"724_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","volume":"36","author":"P Thokala","year":"2018","unstructured":"Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. PharmacoEconomics. 2018;36:509\u201322.","journal-title":"PharmacoEconomics"},{"key":"724_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14737167.2018.1443810","volume":"18","author":"AS Santos","year":"2018","unstructured":"Santos AS, Guerra-Junior AA, Godman B, Morton A, Ruas CM. Cost-effectiveness thresholds: methods for setting and examples from around the world. Expert Rev PharmacoEcon Outcomes Res. 2018;18:277\u201388.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"724_CR42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s41669-020-00211-0","volume":"4","author":"S Bazarbashi","year":"2020","unstructured":"Bazarbashi S, De Vol EB, Maraiki F, Al-Jedai A, Ali AA, Alhammad AM, Aljuffali IA, Iskedjian M. Empirical monetary valuation of a quality-adjusted life-year in the Kingdom of Saudi arabia: a willingness-to-pay analysis. PharmacoEconomics-open. 2020;4:625\u201333.","journal-title":"PharmacoEconomics-open"},{"key":"724_CR43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/13696998.2019.1639186","volume":"22","author":"A Igarashi","year":"2019","unstructured":"Igarashi A, Goto R, Yoneyama-Hirozane M. Willingness to pay for QALY: perspectives and contexts in Japan. J Med Econ. 2019;22:1041\u20136.","journal-title":"J Med Econ"},{"key":"724_CR44","first-page":"547","volume":"70","author":"A Nowicki","year":"2017","unstructured":"Nowicki A, Graczyk P, Farbicka P. Acceptance of the disease and tendency to pay higher health insurance fee by patients with lung cancer. Wiadomosci Lekarskie (Warsaw Poland: 1960). 2017;70:547\u201352.","journal-title":"Wiadomosci Lekarskie (Warsaw Poland: 1960)"},{"key":"724_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2021.08.003","volume":"25","author":"M Schurer","year":"2022","unstructured":"Schurer M, Matthijsse SM, Vossen CY, van Keep M, Horscroft J, Chapman A-M, Akehurst RL. Varying willingness to pay based on severity of illness: impact on health technology assessment outcomes of inpatient and outpatient drug therapies in the Netherlands. Value Health. 2022;25:91\u2013103.","journal-title":"Value Health"},{"key":"724_CR46","doi-asserted-by":"publisher","first-page":"e0122760","DOI":"10.1371\/journal.pone.0122760","volume":"10","author":"K Nimdet","year":"2015","unstructured":"Nimdet K, Chaiyakunapruk N, Vichansavakul K, Ngorsuraches S. A systematic review of studies eliciting Willingness-to-Pay per Quality-Adjusted life year: does it justify CE threshold? PLoS ONE. 2015;10:e0122760.","journal-title":"PLoS ONE"},{"key":"724_CR47","doi-asserted-by":"crossref","unstructured":"Ryen L, Svensson M. The willingness to pay for a QALY: A review of the empirical literature. Karlstad University Working Papers in Economics. 2014.","DOI":"10.1002\/hec.3085"},{"key":"724_CR48","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s10198-022-01437-x","volume":"23","author":"C Steigenberger","year":"2022","unstructured":"Steigenberger C, Flatscher-Thoeni M, Siebert U, Leiter AM. Determinants of willingness to pay for health services: a systematic review of contingent valuation studies. Eur J Health Econ. 2022;23:1455\u201382.","journal-title":"Eur J Health Econ"},{"key":"724_CR49","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S. Methods for the Estimation of the NICE cost effectiveness threshol. Centre Health Econ Res Paper. 2013:119."},{"key":"724_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/amajethics.2021.601","volume":"23","author":"PT Menzel","year":"2021","unstructured":"Menzel PT. How should willingness-to-pay values of quality-adjusted life-years be updated and according to whom? AMA J Ethics. 2021;23:601\u20136.","journal-title":"AMA J Ethics"},{"key":"724_CR51","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jval.2023.02.001","volume":"26","author":"CE Phelps","year":"2023","unstructured":"Phelps CE, Lakdawalla DN. Methods to adjust willingness-to-pay measures for severity of illness. Value Health. 2023;26:1003\u201310.","journal-title":"Value Health"},{"key":"724_CR52","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jval.2019.03.003","volume":"22","author":"CE Phelps","year":"2019","unstructured":"Phelps CE. A new method to determine the optimal willingness to pay in cost-effectiveness analysis. Value Health. 2019;22:785\u201391.","journal-title":"Value Health"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00724-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00724-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00724-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:02:15Z","timestamp":1774562535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00724-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00724-1","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by ethical committee of Tehran University of Medical Sciences by code IR.TUMS.SPH.REC.1404.119.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report there are no competing interests to declare","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}